Bitopertin is at least 4 years away from marketing approval, if it actually manages to traverse P2 and P3. Presuming it actually makes it that far, it won't get expedited review as there is a therapy already approved (Scenesse).
Ann: Appendix 4E and Annual Report 2022, page-19
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.58 |
Change
-0.930(6.00%) |
Mkt cap ! $730.1M | |||
| Open | High | Low | Value | Volume |
| $15.35 | $15.74 | $14.23 | $4.173M | 285.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $14.56 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.58 | 1486 | 2 |
View Market Depth
| Last trade - 16.10pm 09/07/2024 (20 minute delay) ? |
| CUV (ASX) Chart |